Natixis Advisors LLC Buys Shares of 10,838 Artivion, Inc. (NYSE:AORT)

Natixis Advisors LLC acquired a new stake in Artivion, Inc. (NYSE:AORT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,838 shares of the company's stock, valued at approximately $310,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Intech Investment Management LLC raised its holdings in Artivion by 6.6% in the third quarter. Intech Investment Management LLC now owns 10,530 shares of the company's stock valued at $280,000 after acquiring an additional 653 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Artivion by 28.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company's stock valued at $522,000 after purchasing an additional 4,295 shares in the last quarter. FMR LLC raised its stake in Artivion by 28.0% in the third quarter. FMR LLC now owns 115,184 shares of the company's stock valued at $3,066,000 after buying an additional 25,176 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Artivion by 543.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 28,574 shares of the company's stock worth $761,000 after acquiring an additional 24,130 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Artivion by 58.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company's stock valued at $9,074,000 after acquiring an additional 125,668 shares during the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

Several research analysts have recently issued reports on AORT shares. JMP Securities restated a "market outperform" rating and issued a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Stifel Nicolaus cut their target price on Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a research report on Tuesday, February 25th. Finally, Needham & Company LLC reduced their target price on Artivion from $34.00 to $32.00 and set a "buy" rating for the company in a report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Artivion currently has an average rating of "Buy" and an average target price of $31.40.

Artivion Stock Performance

Artivion stock traded up $0.33 during mid-day trading on Wednesday, reaching $25.00. 728,611 shares of the company were exchanged, compared to its average volume of 278,792. The firm's 50-day simple moving average is $27.20 and its two-hundred day simple moving average is $27.63. Artivion, Inc. has a twelve month low of $19.36 and a twelve month high of $32.33. The firm has a market cap of $1.05 billion, a PE ratio of -1,250.00 and a beta of 1.79. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The firm had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. Equities analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Activity at Artivion

In other Artivion news, CFO Lance A. Berry sold 3,259 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $89,003.29. Following the completion of the sale, the chief financial officer now owns 75,805 shares of the company's stock, valued at approximately $2,070,234.55. This trade represents a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jean F. Holloway sold 5,335 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the transaction, the senior vice president now owns 149,799 shares of the company's stock, valued at $4,091,010.69. This represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,799 shares of company stock worth $2,356,223 over the last 90 days. Company insiders own 8.10% of the company's stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.